A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Ocular

• Study eye deemed to be indicated for ranibizumab ITV therapy at the discretion of the retina specialist

Concurrent Ocular Conditions

• Patients legally blind in one or both eyes
• History of or any current clinically relevant intraocular inflammation or ocular inflammatory reaction (any grading from trace and greater is excluded), including non-infectious uveitis or uveitis, or sterile inflammatory reaction after the past ITV injections with any agent
• Active disorder of ocular adnexa and skin in the study eye, including ocular surface infections
• History of or any current indication of excessive bleeding and recurrent hemorrhages, including any prior excessive intraocular (including subconjunctival) bleeding or hemorrhages after ITV injection or intraocular procedures
• Uncontrolled intraocular pressure greater than (>) 25 millimeters of mercury (mmHg) in the study eye (uncontrolled means that it occurs even with intraocular pressure-lowering therapy)
• Use of therapies that are known to be toxic to any ocular tissues within the 6 months prior to enrollment

Prior Ocular Therapies

• Treatment with any ITV injection within the 27 days prior to Day 1
• Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye at any time during the past 3 months

General

• Receipt of any systemic (non-ocular) investigational drug within 3 months prior to Day 1
• Current systemic coagulation or bleeding disorders and history of recurrent hemorrhages
• Intolerance or known reaction to prior biological therapies
• History of other diseases or physical or laboratory examination findings that per the retina specialist represent a contraindication to ranibizumab use in the patient or may represent an unwarranted patient risk.
• Uncontrolled hypertension (systolic >160 mmHg and/or diastolic >100 mmHg while sitting)
• Current systemic infectious disease or a therapy for active infectious disease
• Pregnant or lactating